

National Authority of Medicines and Health Products, I.P.

CERTIFICATE NUMBER : **FT085/SA/001/2021**

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER ^{1, 2}

Part 1

Issued following an inspection in accordance with :
Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Portugal confirms the following:

The manufacturer : ***Catalent Maryland Harmans (BWI)***

Site address : ***7555 Harmans Road, Harmans, Maryland, 21077, United States***

DUNS Number : ***11-695-0534***

Is an active substance manufacturer that has been inspected in accordance with Art. 111(1) of Directive 2001/83/EC .

Other

Distant Assessment

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2020-12-18** , it is considered that it complies with :

- The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC ³
- The principles of GMP for active substances ³ referred to in Article 47 of Directive 2001/83/EC .

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

¹ The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

² Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

³ These requirements fulfil the GMP recommendations of WHO.

Part 2

Manufacture of active substance. Names of substances subject to inspection :

ASTRAZENECA COVID-19 VACCINE (SOLUTION FOR INJECTION)(en)

3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

Active Substance :ASTRAZENECA COVID-19 VACCINE (SOLUTION FOR INJECTION)

3.3	Manufacturing of Active Substance using Biological Processes
	3.3.2 Cell Culture: mammalian 3.3.3 Isolation / Purification
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing 3.6.4 Biological Testing

Clarifying remarks (for public users)

Restricted to manufacturing operations carried out in Suite 9 (Building 1). Based on distant assessment, to support an application for a new type of product and taking into account the complexity of the manufacturing process of the active substance, as well as COVID-19 travel restrictions, the validity of this Certificate is restricted to 18-12-2022.

2021-01-21

Name and signature of the authorised person of the
Competent Authority of Portugal

Confidential
National Authority of Medicines and Health Products,
I.P.

Tel: **Confidential**

EudraGMP